AbbVie Updates on Financial Condition, Senior Notes Maturities

Ticker: ABBV · Form: 8-K · Filed: 2024-01-05T00:00:00.000Z

Sentiment: neutral

Topics: debt, financial-condition, senior-notes

TL;DR

**AbbVie just updated on its debt, specifically detailing various senior notes due from 2024 to 2031.**

AI Summary

AbbVie Inc. filed an 8-K on January 5, 2024, to report on its financial condition and results of operations. This filing specifically mentions various senior notes, including 1.375% Senior Notes due 2024, 1.250% Senior Notes due 2024, 0.750% Senior Notes due 2027, 2.125% Senior Notes due 2028, 2.625% Senior Notes due 2028, 2.125% Senior Notes due 2029, and 1.250% Senior Notes due 2031. For investors, this matters because it provides an update on the company's debt structure and upcoming maturities, which can impact future cash flow and financial flexibility.

Why It Matters

This filing provides transparency into AbbVie's debt obligations, which is crucial for assessing its financial health and ability to manage upcoming maturities. Understanding these details helps investors gauge the company's future financial commitments.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial information and does not indicate any immediate or significant new risks.

Analyst Insight

A smart investor would review AbbVie's upcoming earnings reports and financial statements for more detailed information on how these senior notes will be managed, especially those maturing in 2024, to assess potential impacts on cash flow and debt levels.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the purpose of AbbVie Inc.'s 8-K filing on January 5, 2024?

The 8-K filing by AbbVie Inc. on January 5, 2024, is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically reporting on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.

Which specific senior notes are mentioned in this 8-K filing?

The filing specifically mentions 1.375% Senior Notes due 2024, 1.250% Senior Notes due 2024, 0.750% Senior Notes due 2027, 2.125% Senior Notes due 2028, 2.625% Senior Notes due 2028, 2.125% Senior Notes due 2029, and 1.250% Senior Notes due 2031.

What is the earliest event reported date for this 8-K filing?

The date of the earliest event reported for this 8-K filing is January 5, 2024.

What is AbbVie Inc.'s Central Index Key (CIK) according to the filing?

AbbVie Inc.'s Central Index Key (CIK) is 0001551152.

Where is AbbVie Inc.'s principal executive office located?

AbbVie Inc.'s principal executive office is located at 1 North Waukegan Road, North Chicago, Illinois 60064-6400.

From the Filing

0001551152-24-000002.txt : 20240105 0001551152-24-000002.hdr.sgml : 20240105 20240105160327 ACCESSION NUMBER: 0001551152-24-000002 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240105 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240105 DATE AS OF CHANGE: 20240105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24516198 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 abbv-20240105.htm 8-K abbv-20240105 0001551152 false 0001551152 2024-01-05 2024-01-05 0001551152 exch:XNYS us-gaap:CommonStockMember 2024-01-05 2024-01-05 0001551152 exch:XCHI us-gaap:CommonStockMember 2024-01-05 2024-01-05 0001551152 exch:XNYS abbv:Sec1.375SeniorNotesDue2024Member 2024-01-05 2024-01-05 0001551152 exch:XNYS abbv:Sec1250SeniorNotesDue2024Member 2024-01-05 2024-01-05 0001551152 exch:XNYS abbv:Sec0.750SeniorNotesDue2027Member 2024-01-05 2024-01-05 0001551152 abbv:Sec2.125SeniorNotesdue2028Member exch:XNYS 2024-01-05 2024-01-05 0001551152 abbv:Sec2625SeniorNotesDue2028Member exch:XNYS 2024-01-05 2024-01-05 0001551152 exch:XNYS abbv:Sec2125SeniorNotesDue2029Member 2024-01-05 2024-01-05 0001551152 abbv:Sec1.250SeniorNotesdue2031Member exch:XNYS 2024-01-05 2024-01-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  _____________________________________________________ FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): January 5, 2024   ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware   001-35565   32-0375147 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)  _____________________________________________________ 1 North Waukegan Road North Chicago ,  Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐                       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchan

View on Read The Filing